Cartesian Therapeutics Past Earnings Performance
Past criteria checks 0/6
Cartesian Therapeutics's earnings have been declining at an average annual rate of -4603.1%, while the Biotechs industry saw earnings growing at 19.7% annually. Revenues have been growing at an average rate of 43.9% per year.
Key information
-4,603.1%
Earnings growth rate
-56.3%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 43.9% |
| Return on equity | n/a |
| Net Margin | -493.9% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Cartesian Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 54 | -267 | 39 | 0 |
| 31 Mar 24 | 26 | -288 | 38 | 0 |
| 31 Dec 23 | 26 | -257 | 35 | 0 |
| 30 Sep 23 | 0 | -9 | 1 | 0 |
| 31 Dec 22 | 111 | 35 | 24 | 0 |
| 31 Dec 21 | 85 | -26 | 21 | 0 |
Quality Earnings: RNAC is currently unprofitable.
Growing Profit Margin: RNAC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if RNAC's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare RNAC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RNAC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).
Return on Equity
High ROE: RNAC's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.